Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

Core Viewpoint - Capricor Therapeutics is set to release its financial results for the first quarter of 2025 on May 13, 2025, followed by a conference call to discuss the results and recent corporate updates [1][2]. Company Overview - Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, with its lead product candidate being deramiocel, a cardiac-derived cell therapy [3]. - Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy (DMD) and has shown significant immunomodulatory and anti-fibrotic effects in preclinical and clinical studies [3]. - The company is also utilizing its proprietary StealthX™ platform for the preclinical development of exosome technology aimed at various therapeutic applications, including vaccinology and targeted delivery of therapeutics [3]. Recent Developments - Capricor has entered into an exclusive commercialization and distribution agreement for deramiocel in the United States and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [6].